title: Inflammasome activation and vitiligo/nonsegmental vitiligo progression.
abstract: BACKGROUND
  Polymorphisms of NLR (nucleotide-binding domain and leucine rich repeat containing) family, pyrin domain containing protein 1 (NLRP1) have been found in patients with vitiligo/nonsegmental vitiligo (NSV), and increased NLRP1 expression has been detected in the leading edge of lesional skin biopsies.
  
  
  OBJECTIVE
  To evaluate the presence and intensity of NLRP1 immunostaining in lesional and perilesional skin of patients with vitiligo/NSV and to search for possible correlations between NLRP1 and interleukin (IL)-1β expression, lymphocytic infiltrates and disease activity.
  
  
  METHODS
  Of 14 consecutive vitiligo/NSV patients, eight had active disease [Vitiligo European Task Force (VETF) spreading score +1 to +5], one patient had stable disease and five patients had regressive disease (VETF spreading score -1 to -3). We performed immunostaining for NLRP1, B and T lymphocytes, IL-1β and kallikrein 7 on lesional and perilesional vitiligo skin.
  
  
  RESULTS
  NLRP1 and IL-1β immunostaining in perilesional vitiligo/NSV skin was significantly associated with progressive disease (P = 0·009 and 0·04, respectively) and performed better than the simple detection of lymphocytic infiltrates.
  
  
  CONCLUSIONS
  Our findings suggest that markers of the NLRP1 inflammasome could be a useful test for assessing disease activity in addition to the detection of inflammatory infiltrates in the progressing margins of vitiligo/NSV lesions.
authors.affiliation: National Reference Centre for Rare Skin Diseases, Hôpital St André, CHU de Bordeaux, France.
authors.forename: J
authors.initials: J
authors.lastname: Marie
authors.forename: D
authors.initials: D
authors.lastname: Kovacs
authors.forename: C
authors.initials: C
authors.lastname: Pain
authors.forename: T
authors.initials: T
authors.lastname: Jouary
authors.forename: C
authors.initials: C
authors.lastname: Cota
authors.forename: B
authors.initials: B
authors.lastname: Vergier
authors.forename: M
authors.initials: M
authors.lastname: Picardo
authors.forename: A
authors.initials: A
authors.lastname: Taieb
authors.forename: K
authors.initials: K
authors.lastname: Ezzedine
authors.forename: M
authors.initials: M
authors.lastname: Cario-André
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D058847:Inflammasomes / Q000378:metabolism*; D053583:Interleukin-1beta / Q000378:metabolism; D007610:Kallikreins / Q000378:metabolism; D008214:Lymphocytes / Q000502:physiology; D008297:Male; D008875:Middle Aged; D000070576:NLR Proteins; D014820:Vitiligo / Q000175:diagnosis*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D051017:Apoptosis Regulatory Proteins; D015415:Biomarkers; D058847:Inflammasomes; D053583:Interleukin-1beta; D000070576:NLR Proteins; C427903:NLRP1 protein, human; D007610:Kallikreins